South & Central America Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Embolic Agent and Support Device), Disease Indication (Cancer, Peripheral Vascular Disease, Neurological Disease, Urological and Nephrologi

South & Central America Embolotherapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Embolic Agent and Support Device), Disease Indication (Cancer, Peripheral Vascular Disease, Neurological Disease, Urological and Nephrological Disorder, Gastrointestinal Disorder, and Other), Procedure [Transcatheter Arterial Embolization (TAE), Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT), and Transarterial Chemoembolization (TACE)], and End User (Hospital & Clinic, Ambulatory Surgery Center, and Other End User)

The embolotherapy market in South & Central America is expected to grow from US$ 230.83 million in 2022 to US$ 339.16 million by 2028. It is estimated to grow at a CAGR of 6.6% from 2022 to 2028.

Rising Prevalence of Cancer Fuels Embolotherapy Market in South & Central America

The five most common types of cancer are breast, prostate, cervical, lung, and colorectal. However, of these five cancers, the leading cause of cancer-related death is lung cancer. Even though breast cancer has at least a 25% higher incidence among women, cervical carcinoma was the leading cause of death in 2020. Embolization is used to stop bleeding or block blood flow to a tumor or abnormal area of tissue. It is also used to treat liver and kidney cancer and neuroendocrine tumors. Embolizing agents, including embolic microspheres (beads), are used to restrict the vascular supply of tumors, and can be loaded with chemotherapeutic medicines, which elute and diffuse into the tissue. The vascular embolization device (previously the arterial embolization device) is intended to control hemorrhaging due to aneurysms, certain types of tumors, and arteriovenous malformations. The pipeline embolization device is used for the treatment of large and giant wide-neck intracranial aneurysms in the internal carotid artery. It helps prevent aneurysms and tumors from growing and causing harm to essential organs. Thus, the rising prevalence of cancer cases is creating a high demand for embolotherapy products.

Market Overview



The embolotherapy market in South & Central America is segmented into Brazil, Argentina, and the rest of SAM . In 2021, Brazil held the largest market share. Also, the market in the country is projected to grow at the highest rate during the forecast period. The embolotherapy market in the region is expected to grow in the coming years owing to the rising prevalence of cancer and improving healthcare facilities in the countries. Brazil is the largest revenue-generating country for the embolotherapy market in South & Central America. Moreover, it is one of the fastest-growing economies across the world. Cancer is one of the primary epidemic diseases, and the number of cancer cases has doubled in the past three decades..

South & Central America Embolotherapy Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Embolotherapy Market Segmentation

The South & Central America embolotherapy market is segmented into product, disease indication, procedure, end user, and country.

Based on product, the market is segmented into embolic agents and support devices. The embolic agents segment registered the largest market share in 2022. Based on disease indication, the market is categorized into cancer, neurological diseases, urological and nephrological disorders, peripheral vascular diseases, gastrointestinal disorders, and others. The cancer segment held the largest market share in 2022. Based on procedure, the South & Central America embolotherapy market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization/selective internal radiation therapy, and transarterial chemoembolization (TACE). The transcatheter arterial embolization (TAE) segment held the largest market share in 2022. Based on end user, the South & Central America embolotherapy market is segmented into hospitals and clinics, ambulatory surgical centers, and other end users. The hospitals and clinics segment held the largest market share in 2022. Based on country, the market is segmented into Brazil, Argentina, and Rest of SAM. Brazil dominated the market share in 2022. Abbott Laboratories; Boston Scientific Corporation; Cook Medical LLC; Johnson & Johnson; Medtronic; Acandis GmbH; Balt USA LLC; Stryker Corporation; Guerbet LLC; and Terumo Corporation are the leading companies operating in the embolotherapy market in the region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South & Central America embolotherapy market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the South & Central America embolotherapy market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the embolotherapy market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution